Immuneering (IMRX) News Today $2.04 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Immuneering Co. (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy ratinNovember 20 at 5:26 AM | marketbeat.comImmuneering Corp. Reports Q3 Loss, Highlights ProgressNovember 16, 2024 | markets.businessinsider.comImmuneering’s Promising Outlook: Strong Clinical Progress and Financial StabilityNovember 15, 2024 | markets.businessinsider.comCautious Hold Recommendation on Immuneering Amid Promising Developments and Financial UncertaintiesNovember 15, 2024 | markets.businessinsider.comImmuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $15.00 target price on shares of Immuneering in a research report on Thursday.November 14, 2024 | marketbeat.comImmuneering Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 13, 2024 | globenewswire.comShort Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 6.7%Immuneering Co. (NASDAQ:IMRX - Get Free Report) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,520,000 shares, a decrease of 6.7% from the September 30th total of 1,630,000 shares. Based on an average daily volume of 6,690,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 7.2% of the shares of the company are short sold.October 31, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buyOctober 26, 2024 | marketbeat.comBiotech Shares Rip Following FDA Designation AnnouncementOctober 16, 2024 | theglobeandmail.comImmuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic CancerOctober 15, 2024 | markets.businessinsider.comHere's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn SituationOctober 14, 2024 | finance.yahoo.comRenaissance Technologies LLC Takes Position in Immuneering Co. (NASDAQ:IMRX)Renaissance Technologies LLC purchased a new position in shares of Immuneering Co. (NASDAQ:IMRX - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 349,100 shares of the company's stock, valued at approximately $447,0October 11, 2024 | marketbeat.com384,075 Shares in Immuneering Co. (NASDAQ:IMRX) Purchased by Marshall Wace LLPMarshall Wace LLP purchased a new position in Immuneering Co. (NASDAQ:IMRX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 384,075 shares of the company's stock, valueOctober 10, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and four have issued aOctober 1, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Short Interest Up 98.7% in SeptemberImmuneering Co. (NASDAQ:IMRX - Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 3,020,000 shares, a growth of 98.7% from the August 31st total of 1,520,000 shares. Approximately 14.4% of the shares of the stock are short sold. Based on an average trading volume of 6,040,000 shares, the days-to-cover ratio is currently 0.5 days.September 28, 2024 | marketbeat.com3 Penny Stocks to Watch Now, 9/18/24September 18, 2024 | msn.comImmuneering Co. (NASDAQ:IMRX) Forecasted to Post FY2024 Earnings of ($1.61) Per ShareImmuneering Co. (NASDAQ:IMRX - Free Report) - Equities researchers at Chardan Capital boosted their FY2024 earnings per share (EPS) estimates for Immuneering in a report issued on Monday, September 16th. Chardan Capital analyst G. Livshits now forecasts that the company will post earnings per shaSeptember 18, 2024 | marketbeat.comImmuneering (NASDAQ:IMRX) Stock Quotes, Forecast and News SummarySeptember 17, 2024 | benzinga.comOutperform Rating Reaffirmed for Immuneering’s Stock Amidst Promising IMM-1-104 Phase 2a Study ResultsSeptember 16, 2024 | markets.businessinsider.comETC ISSUANCE O.END ETN (BTCE.DE)September 15, 2024 | finance.yahoo.com(AI1QB.NX)September 15, 2024 | finance.yahoo.comWall Street Set to Open Flat in Friday Trading; Import, Export Prices Decline More Than ExpectedSeptember 15, 2024 | msn.comBiotech Surges Premarket Following Positive Phase 2a ObservationsSeptember 15, 2024 | msn.comPositive Phase 2a Trial Data Reinforces Buy Rating for Immuneering’s StockSeptember 13, 2024 | markets.businessinsider.comImmuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer PatientsSeptember 12, 2024 | globenewswire.comImmuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 29, 2024 | finance.yahoo.comFavourable Signals For Immuneering: Numerous Insiders Acquired StockAugust 28, 2024 | finance.yahoo.comBuy Rating on Immuneering: Fast-Track FDA Designation and Promising Clinical Trials Underpin Positive OutlookAugust 7, 2024 | markets.businessinsider.comImmuneering Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 6, 2024 | finance.yahoo.comWhy is Immuneering (IMRX) Stock Up 24% Today?August 1, 2024 | investorplace.comImmuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic CancerJuly 31, 2024 | globenewswire.com3 Penny Stocks With 735% Average Upside, According to Wall StreetJuly 9, 2024 | 247wallst.comImmuneering to Present at the Jefferies Global Healthcare ConferenceMay 29, 2024 | globenewswire.comImmuneering Corp Class A IMRXMay 19, 2024 | morningstar.comUSA News Group: Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer TreatmentMay 17, 2024 | finanznachrichten.deBuy Rating Affirmed for Immuneering with $8 Price Target Amidst Promising Pipeline and Upcoming Data EventsMay 16, 2024 | markets.businessinsider.comBuy Rating Maintained for Immuneering Amid Promising Clinical Pipeline DevelopmentsMay 8, 2024 | markets.businessinsider.comImmuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | globenewswire.comWe Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth CarefullyMay 7, 2024 | finance.yahoo.comImmuneering Recognizes Melanoma Awareness MonthMay 6, 2024 | globenewswire.comBuy Rating Affirmed: Immuneering’s Lead Asset IMM-1-104 Shows Promise Despite Market SkepticismMay 2, 2024 | markets.businessinsider.comImmuneering (IMRX) Price Target Decreased by 11.43% to 13.55April 17, 2024 | msn.comNeedham & Company LLC Reiterates Buy Rating for Immuneering (NASDAQ:IMRX)Needham & Company LLC reiterated a "buy" rating and set a $15.00 price objective on shares of Immuneering in a research note on Friday.April 12, 2024 | marketbeat.comImmuneering advances pancreatic cancer treatment trialApril 11, 2024 | investing.comImmuneering Corporation: IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 9, 2024 | finanznachrichten.deIMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 9, 2024 | globenewswire.comImmuneering Co. (NASDAQ:IMRX) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy ratApril 9, 2024 | marketbeat.comCormorant Asset Management, Lp Sells 400,000 Shares of Immuneering Co. (NASDAQ:IMRX) StockApril 5, 2024 | insidertrades.comImmuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 3, 2024 | globenewswire.comMizuho Trims Immuneering (NASDAQ:IMRX) Target Price to $8.00Mizuho decreased their price objective on shares of Immuneering from $20.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday.April 2, 2024 | marketbeat.com Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Former Trump advisor releases terrifying warning (Ad)Goldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most important financial story of the decade. Goldman Sachs, the IMF, JP Morgan, Bank of America, and Morgan Stanley have issued warnings. Yet most ordinary Americans have no idea. Now one former Trump advisor is sounding the alarm. “If people knew the full facts, there’d be blood in the streets.” Get the facts and learn how to protect your family now. IMRX Media Mentions By Week IMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMRX News Sentiment▼0.750.44▲Average Medical News Sentiment IMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMRX Articles This Week▼82▲IMRX Articles Average Week Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RPID News QNCX News GBIO News ADAG News IPHA News FATE News ATYR News BNTC News ACB News BMEA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMRX) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMRX Stock Alerts